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Abstract
Background: Evidence-based guidelines for the management of mild traumatic brain injury (mTBI) in the
emergency department (ED) are now widely available, and yet, clinical practice remains inconsistent with the
guidelines. The Neurotrauma Evidence Translation (NET) intervention was developed to increase the uptake of
guideline recommendations and improve the management of minor head injury in Australian emergency
departments (EDs). However, the adoption of this type of intervention typically entails an upfront investment that
may or may not be fully offset by improvements in clinical practice, health outcomes and/or reductions in health
service utilisation. The present study estimates the cost and cost-effectiveness of the NET intervention, as compared
to the passive dissemination of the guideline, to evaluate whether any improvements in clinical practice or health
outcomes due to the NET intervention can be obtained at an acceptable cost.
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Methods and findings: Study setting: The NET cluster randomised controlled trial [ACTRN12612001286831]. Study
sample: Seventeen EDs were randomised to the control condition and 14 to the intervention. One thousand nine
hundred forty-three patients were included in the analysis of clinical practice outcomes (NET sample). A total of 343
patients from 14 control and 10 intervention EDs participated in follow-up interviews and were included in the
analysis of patient-reported health outcomes (NET-Plus sample). Outcome measures: Appropriate post-traumatic
amnesia (PTA) screening in the ED (primary outcome). Secondary clinical practice outcomes: provision of written
information on discharge (INFO) and safe discharge (defined as CT scan appropriately provided plus PTA plus INFO).
Secondary patient-reported, post-discharge health outcomes: anxiety (Hospital Anxiety and Depression Scale), post-
concussive symptoms (Rivermead), and preference-based health-related quality of life (SF6D). Methods: Trial-based
economic evaluations from a health sector perspective, with time horizons set to coincide with the final follow-up
for the NET sample (2 months post-intervention) and to 1-month post-discharge for the NET-Plus sample. Results:
Intervention and control groups were not significantly different in health service utilisation received in the ED/
inpatient ward following the initial mTBI presentation (adjusted mean difference $23.86 per patient; 95%CI − $106,
$153; p = 0.719) or over the longer follow-up in the NET-plus sample (adjusted mean difference $341.78 per patient;
95%CI − $58, $742; p = 0.094). Savings from lower health service utilisation are therefore unlikely to offset the
significantly higher upfront cost of the intervention (mean difference $138.20 per patient; 95%CI $135, $141; p < 0.000).
Estimates of the net effect of the intervention on total cost (intervention cost net of health service utilisation) suggest
that the intervention entails significantly higher costs than the control condition (adjusted mean difference $169.89 per
patient; 95%CI $43, $297, p = 0.009). This effect is larger in absolute magnitude over the longer follow-up in the NET-
plus sample (adjusted mean difference $505.06; 95%CI $96, $915; p = 0.016), mostly due to additional health service
utilisation. For the primary outcome, the NET intervention is more costly and more effective than passive dissemination;
entailing an additional cost of $1246 per additional patient appropriately screened for PTA ($169.89/0.1363; Fieller’s
95%CI $525, $2055). For NET to be considered cost-effective with 95% confidence, decision-makers would need to be
willing to trade one quality-adjusted life year (QALY) for 25 additional patients appropriately screened for PTA. While
these results reflect our best estimate of cost-effectiveness given the data, it is possible that a NET intervention that has
been scaled and streamlined ready for wider roll-out may be more or less cost-effective than the NET intervention as
delivered in the trial.
Conclusions: While the NET intervention does improve the management of mTBI in the ED, it also entails a significant
increase in cost and—as delivered in the trial—is unlikely to be cost-effective at currently accepted funding thresholds.
There may be a scope for a scaled-up and streamlined NET intervention to achieve a better balance between costs and
outcomes.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12612001286831, date registered 12
December 2012.
Keywords: Mild head injury, Mild traumatic brain injury, Emergency medicine, Implementation science, Clinical
practice guideline, Evidence-based practice, Cost-effectiveness
Introduction
Evidence-based guidelines for the management of mTBI
in the ED are now widely available [1], and yet, clinical
practice remains inconsistent with key guideline recom-
mendations (see [2], Table 1). A number of previous
studies have estimated the costs and benefits associated
with adherence to alternative management strategies for
mTBI including selective CT scanning, CT for all pa-
tients, skull radiography for all patients, prolonged ED
observation, 24-h hospital admission, and no treatment
[3–5]. Findings suggest that—at the mean—selective CT
scanning is cost-effective in comparison to other strat-
egies and that alternative criteria for selective CT offer
‘broadly similar costs and quality-adjusted life years’ [3]
(page 1428). However, each of these previous studies
evaluated the cost-effectiveness of perfect adherence to
the evaluated management strategies [6]; ignoring the
fact that achieving perfect adherence is a difficult and
costly undertaking [7–9]. Moreover, each is primarily
concerned with adherence to diagnostic management
strategies. Evidence-based guidelines for the manage-
ment of mTBI in the ED include recommendations that
extend beyond diagnostic management such as provision
of verbal and written patient information upon dis-
charge, and evidence-practice gaps are equally problem-
atic for these recommendations (see [2], Table 1).
The Neurotrauma Evidence Translation (NET) inter-
vention was developed to increase the uptake of three
key recommendations for the management of adult pa-
tients who present to Australian EDs with mTBI [10].
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The three recommendations targeted by the NET inter-
vention are as follows:
 Post-traumatic amnesia (PTA) should be
prospectively assessed in the emergency department
using a validated tool.
 Guideline-developed criteria or clinical decision rules
should be used to determine the appropriate use and
timing of computed tomography (CT) imaging.
 Verbal and written patient information (consisting
of advice, education, and reassurance) should be
provided upon discharge from the emergency
department (INFO).
The development of the NET intervention was informed
by empirical evidence and two theoretical frameworks, se-
lected for their relevance to changing clinician behaviour via
implementation interventions in a complex organisational
environment [10]. Specifically, factors influencing clinical
behaviour change were identified from the Theoretical
Domains Framework [11]; organisational factors likely to in-
fluence the uptake and implementation of interventions in
complex environments such as EDs were identified from
the Model of Diffusion of Innovations in Service Organisa-
tions [12]. This approach yielded an intervention designed
to operate at the level of the clinician and the organisation
and to target factors hypothesised to influence uptake of
practice recommendations in EDs [13, 14].
The NET Trial [2] aimed to test the effectiveness of
the NET intervention for improving management of
mTBI in Australian EDs, as compared with the passive
dissemination of the relevant guideline [15]. The NET
trial estimated the effects of the NET intervention on
clinical practice outcomes (NET sample) and on pa-
tient-reported health outcomes in a smaller sample of
EDs and patients who participated in follow-up inter-
views (NET-Plus sample). Results from the NET Trial
suggest that the NET intervention improves the man-
agement of mTBI in the ED; increasing a patient’s
chances of being appropriately assessed for PTA and of
‘safe discharge’ (Bosch M, McKenzie J, Ponsford JL,
Turner S, Chau M, Tavender EJ, et al.: Evaluation of a
targeted, theory-informed implementation intervention
designed to increase uptake of emergency management
Table 1 Schedule of measures for the economic evaluation
Measures Data collection Timing Source Level
Clinical practice outcomes
Appropriate PTA screening (PTA)1 Chart audit Retrospectively for 2 months
period post-intervention
ED medical records
of eligible patients
Patient
Provision of written patient information (INFO)
Safe discharge (SAFED)2
Clinical patient outcomes and health-related quality of life
Anxiety3 Telephone
interview
Ave. 210 days post discharge (SD 38.5 days;
IQR 181–239; min = 130, max = 321)
Patient self-report Patient
Post-concussive symptoms4
HRQoL5
Direct cost of the intervention
Preparation/delivery time and attendance
for local training sessions
Questionnaire On completion of delivery to all EDs Clinician self-report ED
Direct cost of all other intervention
components
Data abstraction
and interview
On completion of delivery to all EDs Administrative and
financial records
ED
Health care utilisation and costs
Medical and surgical services received in
the ED/inpatient ward (including CT scan)
Chart audit Retrospectively on 2 months period
post-intervention
ED medical records
of eligible patients
Patient
Re-presentation to ED within 1
month of mTBI
Post-discharge mTBI-related
service utilisation
Telephone
interview
Ave. 210 days post discharge
(SD 38.5 days; IQR 181–239; min = 130, max = 321)
Patient self-report Patient
1Primary outcome for the economic evaluation
2Defined as PTA, INFO, and CT where CT denotes whether a CT scan was provided in the presence of a risk factor that justifies the scan (age 65 or older; GCS < 15;
amnesia; suspected skull fracture; vomiting and coagulopathy) [26] (assessed in the cohort of patients for whom risk criteria were recorded only). CT therefore
indicates whether a scan was appropriately provided but not whether a scan was ‘appropriately denied’. CT and SAFED only assessed in the cohort of patients for
whom risk criteria were recorded
3Anxiety measured using the relevant questions in the Hospital Anxiety and Depression Scale giving a score between 0 and 21, higher scores indicate higher
levels of anxiety, and a score > 7 indicative of clinically significant anxiety
4Post-concussion symptoms measured using the 13-item Rivermead scale giving a score between 0 and 52, higher scores indicate greater severity of
post-concussion symptoms
512-item short form health survey (SF-12 v2) to derive SF-12-based SF6D index scores using the UK weights from Brazier and Roberts [20]. SF12-based SF6D index
scores range between 0.350 (the ‘pits’) and 1.000 (full health)
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recommendations regarding adult patients with mild
traumatic brain injury: results of the NET cluster ran-
domised controlled trial, Forthcoming). However, the
improvement in PTA did not clear an a priori specified
threshold for clinical significance and the improvement
in ‘safe discharge’ mainly reflects the improvement in
PTA [2], (Bosch M, McKenzie J, Ponsford JL, Turner S,
Chau M, Tavender EJ, et al.: Evaluation of a targeted,
theory-informed implementation intervention designed
to increase uptake of emergency management recom-
mendations regarding adult patients with mild trau-
matic brain injury: results of the NET cluster
randomised controlled trial, Forthcoming). Detailed re-
sults from the main effectiveness analysis of the NET
Trial are reported elsewhere (Bosch M, McKenzie J,
Ponsford JL, Turner S, Chau M, Tavender EJ, et al.:
Evaluation of a targeted, theory-informed implementa-
tion intervention designed to increase uptake of emer-
gency management recommendations regarding adult
patients with mild traumatic brain injury: results of the
NET cluster randomised controlled trial, Forthcoming).
(Bosch M, McKenzie J, Ponsford JL, Turner S, Chau M,
Tavender EJ, et al.: Evaluation of a targeted, theory-in-
formed implementation intervention designed to increase
uptake of emergency management recommendations re-
garding adult patients with mild traumatic brain injury: re-
sults of the NET cluster randomised controlled trial,
Forthcoming) argued that understanding the impact of
the intervention on health service utilisation and total cost
may be necessary before clear policy recommendations
can be drawn from the NET trial. For example, the NET
intervention has the potential to reduce some categories
of health service utilisation including diagnostic imaging
in the ED and unplanned hospital readmissions. The NET
intervention also entails an upfront investment that may
or may not be fully offset by improvements in clinical
practice, health outcomes, and/or reductions in health ser-
vice utilisation. The economic evaluation described here
will explicitly consider this trade-off; first estimating the
impact of the intervention on health service utilisation
and total cost and then combining treatment effects with
respect to cost (incremental cost) and effectiveness (incre-
mental effectiveness) to quantify the incremental
cost-effectiveness (incremental cost divided by incremen-
tal effectiveness) of the NET intervention.
The complexity of this trade-off has a broader rele-
vance for evidence-based medicine. Closing gaps be-
tween evidence and practice is rarely a simple matter
[16, 17], and changing clinician behaviour has proven
difficult even with tailored, multi-faceted interventions
[18, 19]. On the cost side of the equation, attempts to
maximise effectiveness by adding facets and complexity,
or via the use of tailored rather than ‘off-the-shelf ’ inter-
ventions, will typically add cost and this may or may not
be money well-spent [8, 20]. The present study demon-
strates the importance and value of quantifying
trade-offs between cost and effectiveness and serves as a
reminder that initiatives to increase adherence to guide-
line recommendations should themselves offer good
value for money.
Methods
Study design
The NET study [ACTRN12612001286831] was a cluster
randomised controlled trial (CRT) designed to test the
effectiveness of the NET intervention for improving
management of mTBI in Australian EDs, as compared
with the passive dissemination of the relevant guideline
[15]. For the present study, trial-based economic evalua-
tions were conducted alongside the NET CRT to quan-
tify the incremental cost-effectiveness of NET
intervention in achieving practice change and health
outcomes, as compared to the dissemination of the rele-
vant clinical practice guideline. All analyses were con-
ducted from a health sector perspective. The time
horizons for the inclusion of relevant costs and conse-
quences coincide with the final scheduled follow-up for the
NET sample (2 months post-intervention) and to 1 month
post-discharge for the NET-Plus sample. Ethical approval
for this study was initially obtained from the Alfred Health
Human Research Ethics Committee (approval Number
398/12); local ethics and research governance procedures
were subsequently completed for each study site. Please
refer to our study protocol [2] for a detailed description of
the design of the CRT and methods for the accompanying
trial-based economic evaluations.
Study setting and study sample
The economic evaluations alongside the NET study
made use of the data at the ED, clinician and patient
levels; with recruitment and randomisation procedures
for EDs, clinicians, and patients as described in the
study protocol [2] and main trial report (Bosch M,
McKenzie J, Ponsford JL, Turner S, Chau M, Tavender
EJ, et al.: Evaluation of a targeted, theory-informed im-
plementation intervention designed to increase uptake
of emergency management recommendations regarding
adult patients with mild traumatic brain injury: results
of the NET cluster randomised controlled trial, Forth-
coming). Briefly, 24-h Australian EDs meeting inclusion
criteria whose Directors consented to participate in ei-
ther NET or NET-Plus were allocated to either the
intervention or control group using the method of
minimisation. EDs operating for less than 24 h per day,
EDs without a CT scanner on site, and EDs in specia-
lised hospitals that do not routinely treat adult patients
with TBI (for example, women’s, or children) were ex-
cluded. Based on estimates of required sample size (15
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EDs per group), to detect a clinically significant 20%
change in the primary outcome at the 5% level with ap-
proximately 80% power, we aimed to recruit 34 EDs to
allow for 10% attrition.
For included EDs, a sample of mTBI patients presenting
in the 2 months directly following the local intervention
delivery period was selected for inclusion in chart audit
using the three-step process described by (Bosch M,
McKenzie J, Ponsford JL, Turner S, Chau M, Tavender EJ,
et al.: Evaluation of a targeted, theory-informed imple-
mentation intervention designed to increase uptake of
emergency management recommendations regarding
adult patients with mild traumatic brain injury: results of
the NET cluster randomised controlled trial, Forthcom-
ing). Patients were eligible for inclusion if they were aged
18 or older, had presented to the ED within 24 h of injury,
sustained an acute blunt head trauma, and had a Glasgow
Coma Scale score of 14 or 15 at presentation. Patients
with penetrating injuries or non-traumatic brain-injury
such as stroke were excluded. Patients included in the
chart audit and drawn from NET-Plus EDs were subse-
quently invited to participate in the NET-Plus follow-up
of patient-reported health outcomes. At the clinician level,
a sample of 50 medical and 50 nursing staff was randomly
selected for inclusion in the data collection from a broader
list of medical and nursing staff meeting inclusion/exclu-
sion criteria in each participating ED.
Intervention and comparator
EDs randomised to the control group received a copy of
the relevant guideline [15] and support in quality assur-
ance for data collection (including reminder stickers and
education). EDs randomised to the intervention group re-
ceived the NET intervention—a complex, multi-faceted
intervention that operated at the level of the clinician and
the organisation. The NET intervention included the fol-
lowing components:
(i) Access to the guideline [21],
(ii) One stakeholder meeting per intervention group ED
(1 h duration) between NET clinicians/researchers
and local stakeholders (clinicians and management)
to secure ‘buy-in’ at the ED level;
(iii) Identification of local opinion leaders (nursing and
medical) via the key-informant method (with ED
Directors or Senior Consultants being the key
informant for each ED);
(iv)Delivery of an interactive train-the-trainer workshop to
local opinion leaders (1 day duration) led by content
experts and NET clinicians and incorporating informa-
tion provision and skills training;
(v) Delivery of local workshops (20 min duration) by
local opinion leaders to ED staff using provided
materials; and
(vi) Provision of screening tools and information
booklets in English and translated into five
languages commonly spoken in Australia.
Intervention components were selected to target modifi-
able barriers and enablers for the implementation of key rec-
ommendations regarding the management of mTBI [13, 14].
The design of the NET intervention and its components
have been described in detail elsewhere [2, 10, 14, 22]. The
delivery of the NET intervention and resources required for
each intervention component are described in detail in Add-
itional file 1. Delivery of the comparator or control condition
is described in detail in Additional file 2.
Incremental effectiveness
The primary outcome for the main effectiveness analysis,
appropriate PTA screening of patients with mTBI (based
on chart review), was also specified as the primary out-
come for the economic evaluation. Supplementary ana-
lyses were also conducted for a number of secondary
outcomes. Provision of written information on discharge
from the ED (INFO) and ‘safe discharge’ (SAFED, defined
as CT scan appropriately provided plus PTA plus INFO)
were specified as secondary clinical practice outcomes for
economic evaluation in the NET sample. Patient-reported
measures of anxiety (Hospital Anxiety and Depression
Scale [23, 24]), post-concussive symptoms (13-item River-
mead [25]), and health-related quality of life (SF-12-based
SF6D index scores [26–28])1 were specified as secondary
patient outcomes for economic evaluation in the
NET-Plus sample. Intervention effects with respect to
‘PTA’, ‘INFO’, ‘SAFED’, clinical patient outcomes, and
health-related quality of life were estimated using general-
ised estimating equation (GEE) models as specified for the
main effectiveness analysis (see [2], (Bosch M, McKenzie
J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.:
Evaluation of a targeted, theory-informed implementation
intervention designed to increase uptake of emergency
management recommendations regarding adult patients
with mild traumatic brain injury: results of the NET clus-
ter randomised controlled trial, Forthcoming)) in STATA/
MP 13.1 for Windows [STATA Corp, 2016]. GEE models
appropriately account for correlation of observations clus-
tered within EDs.
Incremental cost
For the NET sample, total cost per patient was calcu-
lated as the sum of per patient intervention costs (calcu-
lated at the ED level and averaged across patients in
each ED) and the per-patient cost of medical and surgi-
cal services received in the ED/inpatient ward following
their initial mTBI presentation (calculated at the patient
level).2 For the NET-Plus sample, the total cost per
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patient additionally includes the per-patient cost of
mTBI-related health service utilisation for a 4-week
period, post-discharge from their initial mTBI presenta-
tion (calculated at the patient level).
Data sources for each component of total cost are
summarised in Table 1 and described in detail in Add-
itional files 1, 2, 3, 4, 5 and 6. Additional files 1 and 2
provide a detailed description of line items and data
sources for delivery of the intervention and control con-
ditions. Additional file 3 reproduces health service util-
isation items from the chart audit used to estimate
resource-use in the ED/inpatient ward. Additional file 4
reproduces health service utilisation items included in
phone interviews with NET-Plus participants and used
to estimate mTBI-related service utilisation in the
post-discharge period. Tables A5-1 and A5-2 in Add-
itional file 5 list unit costs used to convert physical
units of resource use to dollar values for delivery of the
intervention/control conditions and for health service
utilisation, respectively.
Given the characteristic distribution of health costs
(truncated at zero and right-skewed), the importance
of obtaining readily interpretable marginal effects, and
our interest in population-average effects, we mod-
elled intervention effects on total costs using one-part
generalised estimating equation (GEE) models with a
log link rather than transformed ordinary least
squares or two-part models [29]. Specification of the
log link for the GEE models permits natural interpret-
ation of marginal effects on cost without retransfor-
mation [29]. Correlation structure, standard errors,
and controls for confounding variables were as speci-
fied for the main effectiveness analysis (see [2],
(Bosch M, McKenzie J, Ponsford JL, Turner S, Chau
M, Tavender EJ, et al.: Evaluation of a targeted, theo-
ry-informed implementation intervention designed to
increase uptake of emergency management recom-
mendations regarding adult patients with mild trau-
matic brain injury: results of the NET cluster
randomised controlled trial, Forthcoming)). Aside
from preliminary analyses of costs associated with the
delivery of TTT workshops (conducted using Excel
2013), all analyses of total and incremental cost were
conducted using STATA/MP 13.1 for Windows
[STATA Corp, 2016].
Adjustment for differential timing
All costs were expressed in 2015 AUD by attaching 2015
unit costs where available or inflating actual costs to
December quarter 2015 using the all-items Consumer
Price Index [30]. For the within-trial analysis presented
here, all costs and consequences occurred within a
12-month period, and so, treatment effects were calcu-
lated for undiscounted costs and undiscounted benefits.
Incremental cost-effectiveness
Results from the main analysis on the primary outcome
were expressed as additional costs (savings) per patient
appropriately screened for PTA. For secondary clinical
practice outcomes, results were expressed as additional
costs (savings) per patient who received patient informa-
tion upon discharge and per patient safely discharged. For
patient-reported health outcomes in the NET-Plus sample,
results were expressed as additional costs (savings) per
point difference on anxiety questions of Hospital Anxiety
and Depression Scale, additional costs (savings) per point
difference on the Rivermead Post-Concussive Symptoms
(PCS) checklist, and additional costs (savings) per point
difference in SF6D utility index scores. Point estimates for
incremental cost-effectiveness were calculated as the aver-
age treatment effect on total cost per patient divided by
the average treatment effect on the relevant outcome.
Uncertainty
Parametric confidence intervals around the incremental
cost-effectiveness ratio were derived via the application of
Fieller’s Theorem using iprogs.do [31] in STATA/MP 13.1
for Windows [STATA Corp, 2016]. Non-parametric confi-
dence intervals were derived by applying the acceptability
method to a distribution of incremental cost-effectiveness
ratios generated from bootstrap re-estimation of estimated
treatment effects for incremental cost and incremental ef-
fectiveness (i.e. bootstrap re-estimation of results from
main effectiveness models reported in Tables 3 and 4, with
adjustment for minimisation factors and pre-specified
confounders as appropriate). Non-parametric confidence
intervals and bootstrap re-estimation were implemented
using bsceaprogs.do and bmultiv.do [31] in STATA/MP
13.1 or 15.0 for Windows [STATA Corp, 2016; 2017].
Cost-effectiveness acceptability curves (CEACs) were
used to visualise the uncertainty associated with the deci-
sion to replace the comparator with the evaluated inter-
vention. CEACs plot the proportion of draws in the
bootstrapped distribution of cost-effectiveness for which
the intervention is cost-effective, compared to its com-
parator, at varying funding thresholds (also known as
cost-effectiveness thresholds or reference ICERs). In other
words, the CEAC tracks changes in the probability that
the evaluated intervention is cost-effective as the funding
threshold is increased/decreased. For the present study,
CEACs were derived using bsceaprogs.do [31] based on
data generated from bootstrap re-estimation of our esti-
mates of incremental cost and incremental effectiveness
using bmultiv.do [31] in STATA/MP 13.1 or 15.0 for Win-
dows [STATA Corp, 2016; 2017].
Sensitivity analyses were completed using upper/lower
bound estimates of uncertain parameters and varying po-
tentially contentious assumptions. For example, the inclu-
sion of urgency-related group (URG) costs for service use
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in the ED and costs of mTBI-related treatment in the ED
for the base-case analysis carries a risk of double-counting;
URG costs were therefore excluded in sensitivity analyses
to test robustness to this decision. Along similar lines, the
inclusion of diagnosis-related group (DRG) costs for service
use during inpatient admissions and costs of mTBI-related
Table 2 ED and patient characteristics
N (%)/mean (SD) N (%)/mean (SD) N (%)/mean (SD) N (%)/mean (SD)
NET sample NET-Plus sample
Control 1 Intervention 2 Control 3 Intervention 4
ED structural characteristics
Hospital type (private) 1 (6%) 1 (7%) 1 (7%) 1 (10%)
Hospital type (public) 16 (94%) 13 (93%) 13 (93%) 9 (90%)
Trauma unit 3 (18%) 4 (29%) 2 (14%) 3 (30%)
Short stay unit 13 (76%) 10 (71%) 10 (71%) 6 (60%)
Annual presentation rate 2012, mean (SD) 44,710 (22593) 41,255 (16512) 44,592 (25046) 36,852 (16913)
Annual presentation rate 2012, median (IQR) 42,495 (34,313 to 46,690) 41,574 (27,075 to 55,667) 38,816 (32,833 to 52,963) 32,612 (25,646 to 47,189)
Existence of protocol for mTBI 4 (24%) 3 (21%) 3 (21%) 3 (30%)
NET-Plus 14 (82%) 13 (93%) 14 (100%) 10 (100%)
Rurality (regional) 7 (41%) 5 (36%) 6 (43%) 4 (40%)
Patient characteristics
Age 50.9 (23.65) 54.2 (24.93) 53.5 (20.59) 55.2 (21.17)
Sex (% male) 476 (45%) 390 (44%) 105 (48%) 51 (41%)
After hours presentation 748 (71%) 653 (73%) 149 (68%) 90 (72%)
Initial GCS 15 961 (92%) 768 (86%) 213 (98%) 115 (92%)
Initial GCS 14 89 (8%) 125 (14%) 5 (2%) 10 (8%)
Mechanism of injury, incidental fall 492 (47%) 481 (54%) 113 (52%) 65 (52%)
Mechanism of injury, road traffic 58 (6%) 51 (6%) 11 (5%) 10 (8%)
Mechanism of injury, violence/assault 250 (24%) 163 (18%) 36 (17%) 15 (12%)
Mechanism of injury, sport 62 (6%) 55 (6%) 17 (8%) 11 (9%)
Mechanism of injury, others 179 (17%) 137 (15%) 41 (19%) 24 (19%)
Mechanism of injury, unclear/not reported 9 (0.9%) 6 (0.7%) 0 (0.0%) 0 (0.0%)
Presence other injuries (outside head) 508 (48%) 516 (58%) 105 (48%) 63 (50%)
Alcohol/illicit drug involvement 237 (23%) 206 (23%) 28 (13%) 15 (12%)
Pre-existing coagulopathy or
anti-coagulant or anti-platelet drugs
175 (17%) 165 (18%) 37 (17%) 17 (14%)
Known previous
neurological condition
202 (19%) 191 (21%) 26 (12%) 13 (10%)
Known neurosurgery 14 (1.3%) 18 (2.0%) 2 (0.9%) 3 (2.4%)
Scalp laceration 532 (51%) 464 (52%) 130 (60%) 67 (54%)
Scalp haematoma 400 (38%) 372 (42%) 79 (36%) 42 (34%)
Clinical suspicion of skull fracture 51 (4.9%) 57 (6%) 8 (3.7%) 8 (6%)
Loss of consciousness 186 (18%) 155 (17%) 50 (23%) 18 (14%)
Vomiting 56 (5%) 49 (5%) 12 (6%) 4 (3.2%)
Headache 259 (25%) 231 (26%) 44 (20%) 37 (30%)
Post traumatic seizure 3 (0.3%) 6 (0.7%) 0 (0.0%) 2 (1.6%)
Focal neurological deficit 21 (2.0%) 13 (1.5%) 5 (2.3%) 3 (2.4%)
1Number of patients = 1050; numbers of clusters = 17
2Number of patients = 893; number of clusters = 14
3Number of patients = 218; number of clusters = 14
4Number of patients = 125; number of clusters = 10
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treatment during inpatient admissions carries a risk of
double-counting. However, the inclusion of DRG costs also
carries the risk of an additional possible bias, arising from
difficulties in identifying mTBI-related admissions and the
potential for misclassification of a small number of high-cost
admissions to exert undue influence on results. For this rea-
son, DRG costs were excluded from the base-case analysis
but included alongside costs of mTBI-related treatment dur-
ing inpatient admissions in sensitivity analysis.
Results
Participants
A total of 1943 patients from 17 control and 14 inter-
vention EDs (control: n = 1050; intervention: n = 893)
were included in the analysis of clinical practice out-
comes (NET sample). A total of 343 patients from 14
control and 10 intervention EDs (control: n = 218; inter-
vention: n = 126) participated in follow-up interviews
and were included in the analysis of patient-reported
health outcomes (NET-Plus sample). Table 2 summarises
ED and patient characteristics at baseline for treatment
and control groups in both NET and NET-Plus samples.
Incremental effectiveness
Results regarding the effect of the NET intervention on
clinical practice outcomes (based on chart audit for treated
patients), proxy measures of clinical practice (based on clin-
ician self-report and behavioural simulation), and clinical
outcomes (based on patient self-report) have been reported
in detail elsewhere (Bosch M, McKenzie J, Ponsford JL,
Turner S, Chau M, Tavender EJ, et al.: Evaluation of a tar-
geted, theory-informed implementation intervention de-
signed to increase uptake of emergency management
recommendations regarding adult patients with mild trau-
matic brain injury: results of the NET cluster randomised
controlled trial, Forthcoming). Table 3 provides a brief
summary of results from the main effectiveness analysis
that underpin the economic evaluations reported here. On
the primary outcome for the economic evaluation, appro-
priate PTA screening (based on chart review), patients
treated in intervention EDs were 14% more likely to have
been treated in line with guideline recommendations than
were patients in control EDs (adjusted absolute risk differ-
ence 13.63%; 95%CI 8.3%, 19.0%; p < 0.001). On the second-
ary clinical practice outcome, provision of written patient
information (INFO), intervention and control group
Table 3 Effect of the intervention on clinical practice and patient outcomes
Variable No. of patients (EDs) N (%)/mean (SE) Increment,
raw (95%CI)^
Increment,
adjusted (95%CI)Rx Control Rx Control
Clinical practice outcomes (NET sample)
PTA1 893 (14) 1050 (17) 117 (13.1%) 12 (1.1%) 11.96% (9.8, 14.1) 13.63% (8.3, 19.0)†
INFO 785 (14) 944 (17) 160 (20.4%) 175 (18.5%) 1.84% (− 1.9, 5.6) 3.15% (− 3.0, 9.3)†
SAFED2 402 (14) 413 (17) 14 (3.5%) 0 (0%) 3.49% (1.0, 6.0) –
Clinical outcomes and quality of life (NET-Plus sample)
Anxiety3 125 (10) 218 (14) 3.43 (0.32) 4.27 (0.27) − 0.83 (− 1.69, 0.02) − 0.52 (− 1.34, 0.30)††
Rivermead4 125 (10) 218 (14) 4.73 (0.49) 6.68 (0.59) − 1.96 (3.65, 0.26) − 1.15 (− 2.77, 0.48)††
HRQoL5 123 (10) 208 (14) 0.805 (0.01) 0.776 (0.01) 0.029 (− 0.00, 0.06) 0.030 (− 0.00, 0.06)‡
^Increment, raw = unconditional difference in absolute risk or average scores due to exposure to the intervention from two sample t test with equal variances
†Increment, adjusted = difference in absolute risk due to exposure to the intervention; adjusted for the following minimisation factors and pre-specified
confounders: age, sex, out_of_hours, rurality, mTBI protocol, ED participation in NET-Plus, and annual_presentation_rate. Estimates derived from margins,
dydx(i.study_group) after xtgee, family(binomial) link(logit) corr(exchangeable) vce(robust) to account for within-cluster correlation structure and yielding cluster-
robust standard errors even if the correlation structure is misspecified
††Increment, adjusted = difference in average scores due to exposure to the intervention; adjusted for the following minimisation factors and pre-specified
confounders: age, sex, out_of_hours, rurality, mTBI protocol, and annual_presentation_rate. Estimates derived from margins, dydx(i.study_group) after xtgee,
family(Gaussian) link(identity) corr(independent) vce(robust) to account for within-cluster correlation structure and yielding cluster-robust standard errors even if the
correlation structure is misspecified
‡Increment, adjusted = difference in average scores due to exposure to the intervention; adjusted for the following minimisation factors and pre-specified
confounders: age, sex, out_of_hours, rurality, mTBI protocol, and annual_presentation_rate. Estimates derived from margins, dydx(i.study_group) after xtgee,
family(Gaussian) link(log) corr(independent) vce(robust) to account for within-cluster correlation structure and yielding cluster-robust standard errors even if the
correlation structure is misspecified
1Primary outcome for the economic evaluation
2Defined as PTA, INFO, and CT where CT denotes whether a CT scan was provided in the presence of a risk factor that justifies the scan (age 65 or older; GCS < 15;
amnesia; suspected skull fracture; vomiting and coagulopathy) [26] (assessed in the cohort of patients for whom risk criteria were recorded only). CT therefore
indicates whether a scan was appropriately provided but not whether a scan was ‘appropriately denied’. CT and SAFED only assessed in the cohort of patients for
whom risk criteria were recorded
3Anxiety measured using the relevant questions in the Hospital Anxiety and Depression Scale giving a score between 0 and 21, higher scores indicate higher
levels of anxiety
4Post-concussion symptoms measured using the 13-item Rivermead scale giving a score between 0 and 52, higher scores indicate greater severity of
post-concussion symptoms
5SF-12v2-based SF6D index scores calculated using weights from Brazier and Roberts [20]. SF-12v2-based SF6D index scores range between 0.350 (the ‘pits’) and
1.000 (full health)
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patients faced about the same chance of being treated in
line with guideline recommendations (adjusted absolute
risk difference 3.15%; 95%CI − 3.0%, 9.3%; p = 0.316). For
the composite indicator of clinical practice, ‘safe discharge’
(SAFED, defined as CT scan appropriately provided plus
PTA plus INFO), patients treated in intervention group
EDs were more likely to meet the criteria for ‘safe discharge’
(absolute risk difference 3.49%; 95% CI 1.0%, 6.0%; p =
0.0091); with this result being largely driven by the differ-
ence in appropriate PTA.
For clinical patient outcomes (NET-Plus sample), there
was no statistically significant difference between inter-
vention and control groups for anxiety (adjusted mean
difference − 0.52; 95% CI − 1.34–0.30; p = 0.216) or
post-concussion symptoms (adjusted mean difference
− 1.15; 95% CI − 2.77–0.48; p = 0.167). Finally, SF6D
HRQoL scores were higher in the intervention group
than in the control group (adjusted mean difference
0.03; 95% CI − 0.00–0.06, p = 0.053). However, this
difference fell just short of the pre-specified 0.05 level
of statistical significance and it is not clear that the
effect is sufficiently large to be considered clinically
significant [32, 33].
Incremental cost
The total cost of delivering the NET intervention to the
14 EDs and 893 patients included in the intervention
group was just over $124,000 or $139 per patient. Total
costs for each component of the NET intervention are
detailed in Additional file 1: Table A1-1. The total cost
of delivering the control condition to the 17 EDs and
1050 patients in the control group was just under $850
or less than $1 per patient. The total costs for each
component of the control condition are detailed in
Additional file 2: Table A2-1. These figures demonstrate
the much larger upfront cost of the NET intervention
(mean difference $138.20; 95% CI $135, $141; p < 0.000).
The total cost of medical and surgical services re-
ceived in the ED/inpatient ward following the initial
mTBI presentation was estimated at $826 in the inter-
vention group and $777 in the control group (adjusted
mean difference $23.86; 95% CI − $106, $153; p =
Table 4 Effect of the intervention on Rx cost, HSU cost, and total cost (per patient)
Variable No. of patients (EDs) Mean (SE) Incremental cost,
raw (95%CI)†
Incremental cost,
adjusted (95%CI)‡Rx Control Rx Control
NET
Rx Cost
Base-case 893 (14) 1050 (17) $139.0 (1.6) $0.8 (0.0) $138.20 (135,141) –
No URG 893 (14) 1050 (17) $139.0 (1.6) $0.8 (0.0) $138.20 (135,141) –
HSU Cost
Base-case 893 (14) 1050 (17) $825.9 (44) $777.4 (33) $48.52 (− 57, 154) $23.86 (− 106,153)
No URG 893 (14) 1050 (17) $354.0 (42) $315.7 (31) $38.35 (− 62, 139) -$1.08 (− 125,122)
Total Cost
Base-case 893 (14) 1050 (17) $964.9 (44) $778.2 (33) $186.72 (81, 292) $169.89 (43, 297)
No URG 893 (14) 1050 (17) $493.0 (42) $316.5 (31) $176.55 (76, 277) $159.96 (39, 281)
NET-Plus, including post-NET HSU
Rx Cost
Base-case 126 (10) 218 (14) $143.8 (4.6) $0.8 (0.0) $142.96 (136,150) –
No URG 126 (10) 218 (14) $143.8 (4.6) $0.8 (0.0) $142.96 (136,150) –
HSU Cost
Base-case 126 (10) 218 (14) $980.8 (235) $738.5 (72) $242.38 (− 156,640) $341.78 (− 58, 742)
No URG 126 (10) 218 (14) $526.6 (233) $276.5 (66) $250.06 (− 137,638) $338.54 (− 56, 733)
Total Cost
Base-case 126 (10) 218 (14) $1124.6 (235) $739.3 (72) $385.34 (− 12, 783) $505.06 (96, 915)
No URG 126 (10) 218 (14) $670.3 (233) $277.3 (66) $393.02 (− 6, 780) $543.49 (116, 971)
†Incremental cost, raw = unconditional difference in cost per patient due to exposure to the intervention from two sample t test with equal variances
‡Incremental cost, adjusted = difference in cost due to exposure to the intervention; adjusted for the following minimisation factors and pre-specified
confounders: age, sex, out_of_hours, rurality, mTBI protocol, ED participation in NET-Plus, and annual_presentation_rate. Estimates derived from margins,
dydx(i.study_group) after xtgee, family(gamma) link(log) corr(exchangeable) vce(robust) to account for within-cluster correlation structure and yielding cluster-robust
standard errors even if the correlation structure is misspecified
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0.719). When combined with intervention delivery
costs, the total cost of the NET intervention in the
2 months post-intervention was $965 as compared to
$778 for the control condition (adjusted mean differ-
ence $169.89; 95% CI $43, $297; p = 0.009).
Results are qualitatively similar over the longer follow-up
in the NET-Plus sample. The NET intervention does not
appear to deliver savings in health service utilisation (ad-
justed mean difference $341.78 per patient; 95%CI − $58,
$742; p = 0.094). Savings from lower health service utilisa-
tion are therefore unlikely to offset the significantly higher
upfront cost of the intervention. Once again, estimates of
the net effect of the intervention on total cost (intervention
delivery cost net of health service utilisation) suggest that
the intervention entails significantly higher costs than the
control condition (adjusted mean difference $505.06;
95%CI $96, $915; p = 0.016). Table 4 summarises estimation
of group totals and increments for intervention delivery,
health service utilisation, and total cost.
Incremental cost-effectiveness
The base-case analysis on the primary outcome sug-
gests that the NET intervention is more costly and
more effective than passive dissemination, entailing an
additional cost of $1246 per additional patient appro-
priately screened for PTA ($169.89/0.1363). Confidence
Table 5 Incremental cost-effectiveness for clinical practice and patient outcomes
Variable ΔC ΔE ΔC / ΔE Parametric (95%CI)† Non-parametric (95%CI)‡
Clinical practice outcomes (NET sample)
PTA1 $169.89 (43, 297) 0.1363 (0.083, 0.190) $1246 ($525, $2055) ($595, $2066)
INFO2 $169.89 (43, 297) 0.0315 (− 0.030, 0.093) $5393 ($1672,− $18,125) ($1909, − $22,865)
SAFED3 $169.89 (43, 297) 0.0349 (0.010, 0.060) $4868 ($1882, $11928) ($2093, $11574)
Clinical outcomes and quality of life (NET-Plus sample)
HADS Anxiety4 $505.06 (96, 915) − 0.52 (− 1.34, 0.30) $971^ ($132, − $1086) ($215, − $1084)
Rivermead PCS5 $505.06 (96, 915) − 1.15 (− 2.77, 0.48) $441^ ($54, − $1270) ($90, − $1346)
SF6D HRQoL6 $505.06 (96, 915) 0.030 (− 0.00, 0.06) $16,948 ($2015,-$367,759) ($3796,-$314,637)
†Parametric CIs derived via Fieller’s Theorem using iprogs.do [25] based on treatment effects reported in Tables 3 and 4 and using standard errors and correlations
calculated from non-parametric bootstrap re-estimation
‡Non-parametric CIs derived via acceptability method using bsceaprogs.do [25] based on the data generated from bootstrap re-estimation of our estimates of
incremental cost and incremental effectiveness using bmultiv.do [25]
1Cost per patient appropriately screened for PTA (primary outcome)
2Cost per patient who received written patient information upon discharge (INFO)
3Cost per safe discharge (SAFED) where SAFED defined as CT scan appropriately provided plus PTA plus INFO
4Cost per point improvement on anxiety questions of Hospital Anxiety and Depression Scale (HADS), higher scores indicate higher levels of anxiety
5Cost per point improvement on the Rivermead post-concussive symptoms scale, higher scores indicate greater severity
6Cost per point improvement in SF6D index scores, higher scores indicate higher HRQoL
^Calculated as ΔC/− ΔE to reflect the fact that higher scores indicate greater severity for HADS and Rivermead
Fig. 1 Cost-effectiveness acceptability curve for the primary outcome (PTA)
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intervals around the base-case point estimate suggest
that—given a sufficiently high funding threshold for the
outcome of interest—we can be at least 95% confident
that the NET intervention represents good value in
comparison to passive dissemination. Upper confidence
limits from parametric and non-parametric 95%CIs are
$2055 and $2066 respectively, and so, if the funding
threshold sits at around $2000 per patient appropriately
screened for PTA, then we can be confident that NET
delivers good value.
At lower funding thresholds, this finding is reversed and
we can be 95% confident that the NET is not cost-effective
when compared against passive dissemination. Lower confi-
dence limits from parametric and non-parametric 95%CIs
are $525 and $595 respectively, and so, if the funding thresh-
old sits at around $500 per patient appropriately screened for
PTA, then we can be 95% confident that passive dissemin-
ation delivers better value than the NET intervention. Table 5
summarises results from the cost-effectiveness analysis, in-
cluding parametric and non-parametric 95%CIs.
Figure 1 gives the cost-effectiveness acceptability curve
(CEAC) for the primary outcome. The CEAC (solid blue
line) plots the relative frequency, or probability, that the
NET intervention is cost-effective, compared to passive
Fig. 2 Cost-effectiveness plane and cost per additional patient appropriately screened for PTA (primary outcome)
Fig. 3 Cost-effectiveness plane and cost per point improvement on HADS
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dissemination at varying levels of the funding threshold
expressed in terms of cost per additional patient appro-
priately screened for PTA. The green and red horizontal
lines intersect the CEAC where the NET intervention is
cost-effective for 97.5% and 2.5% of the distribution re-
spectively, at funding thresholds of $2066 and $595 per
patient appropriately screened for PTA (corresponding
with upper and lower confidence limits estimated via the
acceptability method). For intermediate thresholds (between
the upper and lower confidence limits), we can no longer
be so confident that one or other of the two alternatives
represents better value for money. For decision-makers in-
terested in lower levels of confidence, NET is the most
cost-effective alternative for over 50% of the distribution if
the funding threshold exceeds $1250 per patient appropri-
ately screened for PTA.
For PTA and SAFED, we have pattern 1 findings, with
the scatter of cost-effect pairs on the cost-effectiveness
plane restricted to the northeast (NE) quadrant indicat-
ing that the NET intervention is statistically significantly
more costly and more effective than passive dissemin-
ation [31]. Figure 2 shows the scatter on the
cost-effectiveness plane for PTA, providing a graphical
description of pattern 1 findings. For INFO, HADS Anx-
iety, Rivermead PCS, and SF6D HRQoL, we have pattern
2 findings, with the scatter of cost-effect pairs on the
cost-effectiveness plane spanning the NE and northwest
(NW) quadrants indicating that the NET intervention
carries a statistically significantly greater cost than pas-
sive dissemination but with no significant difference on
the relevant outcome [31]. For pattern 2 findings, the
point estimate appears to sit outside the upper and
lower confidence limits reported in Table 5, an artefact
arising from discontinuities in cost-effectiveness ratios
as we move between quadrants on the cost-effectiveness
plane. Figure 3 demonstrates the relative position of the
point estimate, the scatter, and 95% confidence limits on
the cost-effectiveness plane for cost per point improve-
ment on HADS Anxiety and confirms that the point esti-
mate is bounded by upper and lower confidence limits for
pattern 2 findings.
For INFO, HADS Anxiety, Rivermead PCS, and SF6D
HRQoL, there is no funding threshold at which we can be
95% confident that the NET intervention represents good
value compared with passive dissemination. However,
given a sufficiently low funding threshold for the outcome
of interest, we can be at least 95% confident that the NET
intervention represents poor value in comparison to pas-
sive dissemination. For HADS, lower confidence limits
from parametric and non-parametric 95%CIs are $132
and $215 respectively, and so, if the funding threshold sits
at around $100 per point improvement on the HADS,
then we can be 95% confident that passive dissemination
delivers better value than the NET intervention.
For decision-makers interested in lower levels of confi-
dence, it is still possible to identify a funding threshold for
INFO, HADS Anxiety, Rivermead PCS, and SF6D HRQoL
at which NET is the most cost-effective alternative for a
proportion of the distribution (e.g. for over 50% and 80% of
the distribution). NET is the most cost-effective alternative
for over 50% of the distribution if the funding threshold ex-
ceeds $17,000 per point improvement in SF6D index
scores, and for over 80% of the distribution if the funding
threshold exceeds $34,000 per point improvement in SF6D
index scores. For other outcomes, NET was the most
cost-effective alternative with 80% probability if the funding
threshold exceeds $13,000 per additional patient provided
with written patient information, $4500 per point improve-
ment on HADS, and $1000 per point improvement on the
Rivermead. Full results available upon request.
Sensitivity analysis
Table 5 reports results from the cost analysis after exclud-
ing URG costs to test sensitivity to double counting where,
in the base-case, URG costs for service use in the ED (less
average imaging costs) have been included alongside costs
of mTBI-related treatment in the ED. Results after exclud-
ing URG costs are qualitatively identical to results from the
base-case analysis. On the primary outcome, the NET inter-
vention is more costly and more effective than the passive
dissemination of the relevant guideline (ΔC/ΔE = $159.96/
0.1363 = $1174). Confidence intervals around this point es-
timate suggest that—provided that the funding threshold is
above $1958 per additional patient appropriately screened
for PTA—we can be at least 95% confident that the delivery
of the NET intervention represents good value in compari-
son to passive dissemination. If, on the other hand, the
funding threshold for the primary outcome is less than
$469 per additional patient appropriately screened for PTA,
then we can be 95% confident that the NET intervention is
less cost-effective than passive dissemination. NET is the
most cost-effective alternative for over 50% of the distribu-
tion if the funding threshold exceeds $1200 per additional
patient appropriately screened for PTA.
While results were insensitive to inclusion/exclusion
of URG costs, the same cannot be said for inclusion/ex-
clusion of diagnosis-related group (DRG) costs to cap-
ture the cost of inpatient admissions. In the base-case
analysis, the total cost of the NET intervention in the
2 months post-intervention was $965 as compared to
$778 for the control condition (adjusted mean difference
$169.89; 95% CI $43, $297; p = 0.009). Including DRG
costs alongside costs of mTBI-related treatment during
inpatient admissions had the effect of increasing group
averages ($1838 versus $1385) and inflating incremental
cost (adjusted mean difference $452.91; 95% CI $150,
$756; p = 0.003), with predictable consequences for in-
cremental cost-effectiveness across all primary and
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secondary outcomes. Full results from the sensitivity
analyses are available on request.
Discussion
Results suggest that the NET intervention is more costly
and more effective than passive dissemination for im-
proving management of mTBI in the ED and that—given
sufficiently high funding thresholds for improvements in
PTA and safe-discharge—we can be at least 95%
confident that the NET intervention represents good
value in comparison to passive dissemination. Direct es-
timates of funding thresholds for PTA and safe discharge
are not available and it was not feasible to derive our
own estimates as part of the NET study. Further thought
is therefore required in order to translate our findings
into recommendations for policy and practice.3
Funding thresholds for more commonly used mea-
sures of health gain such as quality-adjusted life years
(QALYs) have previously been estimated or proposed for
different jurisdictions but vary widely and the level and
meaning of these funding thresholds has recently be-
come contested [34, 35].4 For any funding threshold
expressed in terms of cost per QALY gained, we can cal-
culate ‘bounds’ on the relationship between PTA and
QALYs that would need to hold in order for NET to be
considered cost-effective. Moreover, we can conduct this
exercise for different levels of the cost per QALY thresh-
old in order to evaluate the sensitivity of our findings to
an uncertain threshold. In order for the NET interven-
tion to be considered cost-effective with 95% confidence
at a funding threshold of $50,000 per QALY, each add-
itional patient appropriately screened for PTA would
need to generate ≥ 0.04 additional QALYs (at least
2 weeks of additional life expectancy in full health).5 For
a higher (but still plausible) threshold of $100,000 per
QALY, each additional patient appropriately screened for
PTA would need to generate ≥ 0.02 additional QALYs (at
least 1 week of additional life expectancy in full health).
For a lower threshold (closer to recent estimates) of
$25,000 per QALY, each additional patient appropriately
screened for PTA would need to generate ≥ 0.08 add-
itional QALYs (nearly 4.5 weeks of additional life expect-
ancy in full health). Similar trade-offs can be calculated
for other outcomes and at other confidence levels.
To put this in context, recent estimates of the popula-
tion burden of disease for New Zealand suggest that mTBI
imposes a total burden of 3277 years of life lost due to dis-
ability [36]. Assuming mTBI accounted for 70% of the
527,400 New Zealanders who had experienced at least one
TBI, mTBI imposes an average burden of less than 3 days
of life lost due to disability per mTBI patient [36]. The
average per patient burden of mTBI is therefore less than
the average per patient health gain that would have to be
generated in order for us to be 95% confident that the
NET intervention is cost-effective.
For SF6D index scores, we can obtain a more direct
comparison against funding thresholds expressed in cost
per QALY terms. While SF6D index scores were not ex-
plicitly combined with duration to calculate QALYs, we
can calculate an implicit threshold per point improve-
ment in SF6D index scores under different assumptions
regarding the duration over which observed SF6D index
scores persist and compare this to funding thresholds of
$50,000 and $100,000 per QALY. In order for the NET
intervention to be considered cost-effective with 80%
confidence, the SF6D index scores observed in the
NET-Plus sample would need to persist for more than
8 months if we assume a funding threshold of $50,000
per QALY, for more than 4 months if we assume a fund-
ing threshold of $100,000 per QALY, and for more than
16 months if we assume a funding threshold of $25,000
per QALY.6
In interpreting our results, several issues should be
borne in mind. First, the NET study and main effective-
ness analyses had both strengths and limitations that
have been documented elsewhere (Bosch M, McKenzie
J, Ponsford JL, Turner S, Chau M, Tavender EJ, et al.:
Evaluation of a targeted, theory-informed implementa-
tion intervention designed to increase uptake of emer-
gency management recommendations regarding adult
patients with mild traumatic brain injury: results of the
NET cluster randomised controlled trial, Forthcoming).
To the extent that the study design and main effective-
ness results underpin the cost-effectiveness analyses re-
ported here, then our findings regarding
cost-effectiveness are subject to the strengths and limita-
tions of the NET study and main effectiveness analyses.
Key strengths of the NET study with particular relevance
to the cost-effectiveness analysis include the use of a sys-
tematic process to design a multi-faceted intervention,
objective measures of clinical practice, and collection of
data to inform a process evaluation. With regards to lim-
itations of the NET study, the difficult task of identifying
patients for inclusion in chart audit and then recruiting
patients into the NET-Plus sample resulted in missing
data on secondary health outcomes and raised the po-
tential for selection bias. Along similar lines, secondary
clinical outcomes could only be assessed for a subset of
patients, potentially resulting in selection bias. While re-
sults from supplementary sensitivity analyses (see Add-
itional file 7) suggest that findings from the economic
evaluation reported here are robust to any such selection
bias, results for secondary outcomes are for a subset of
the full study sample and should be interpreted with
caution.
Second, the present study estimates the relative cost-
effectiveness of the intervention as implemented and
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may not reflect the relative cost-effectiveness under a
wider roll-out. The NET intervention operates on a
train-the-trainer model and relies on participation at the
organisation level (to permit access to ED staff ), at the
ED level (to identify local opinion leaders), at the level of
local opinion leaders (to attend TTT workshops and de-
liver local workshops), and at the clinician level (to at-
tend local workshops). While participation in the
context of the trial was not always consistent with maxi-
mising the effectiveness of the intervention,7 some level
of participation was achieved at the organisation, ED,
opinion-leader, and clinician levels in the majority of
intervention group EDs. This may not be the case in the
broader sample of Australian EDs meeting our inclu-
sion/exclusion criteria, some or all of which may be tar-
geted in a wider roll-out of the NET intervention.
While a lower level of participation in any wider roll-out
might be expected to render the NET intervention less
cost-effective, it is also possible that a NET intervention
that has been scaled and streamlined ready for wider
roll-out may be more cost-effective than the NET interven-
tion as delivered in the trial. Of particular note, the TTT
workshops accounted for over $70,000 or 56% of the total
cost of delivering the NET intervention to the 14 interven-
tion group EDs participating in the NET trial. While
scale-up may require delivery of additional TTT workshops
and would necessitate attendance by local opinion leaders
from a larger number of EDs, there may also be scope to
increase the number of local opinion leaders trained per
workshop. That is to say, it may be possible to double the
number of EDs attending the TTT workshop component
of the NET intervention at much less than double the esti-
mated cost of delivery.8 Moreover, there may be scope to
reduce travel time and direct travel costs where scale-up re-
quires delivery of additional TTT workshops. For example,
TTT workshops could be scheduled at a wider range of lo-
cations or over a wider range of dates, allowing local opin-
ion leaders to attend a TTT workshop in their home city
rather than interstate. Finally, there may be scope to dra-
matically reduce the cost of TTT workshops using different
modes of delivery such as live webinars and/or distribution
of digital recordings, potentially resulting in a better balance
between costs and effects.
Third, our estimate of incremental cost excludes differ-
ences in health service utilisation that may persist beyond
the time horizon for the NET-Plus sample. Extending our
analysis out to the longer follow-up in the NET-plus sample
entailed a threefold increase in average incremental cost,
and it is possible that we would see a further divergence be-
tween intervention and control groups over an even longer
time horizon. Alternatively, the observed intervention effect
with respect to health service utilisation may diminish over
time; though it is unlikely that we would see a reversal in
the observed trend (i.e. lower rather than higher health
service utilisation in the treatment group) that would invali-
date the results reported here. Nonetheless, the availability
of multiple time-points for patient-reported health service
utilisation and patient-reported health outcomes in the
NET-Plus sample would have allowed us to provide a more
complete exploration of the sensitivity of our findings to
changes in time horizon.
Fourth, we observed treatment effects with respect to
clinical practice and health outcomes only in the study
sample and only during the study period. Cost-effectiveness
may have been underestimated if treatment effects with re-
spect to clinical practice and health outcomes were also inci-
dent upon patients who were treated in intervention-group
EDs during the study period but who were not included in
the study sample. Similarly, cost-effectiveness may have been
underestimated if improvements in patient management ob-
served during the study period persisted beyond the
2-month window from which eligible patients were selected
for chart audit and subsequent follow-up of patient-report
health outcomes. It may not be immediately apparent how
such a bias could arise. The NET intervention operates at
the level of the clinician and the organisation, and so inter-
vention costs are semi-fixed in the sense that the cost of de-
livering treatment effects to one patient (as a consequence of
providing all intervention components to one clinician in
one ED) is exactly the same as the cost of delivering treat-
ment effects to the total number of mTBI patients treated by
one clinician in one ED (for as long as any behaviour change
persists). Cost per patient is therefore a function of the num-
ber of patients in receipt of the treatment effect, and it may
be possible to spread semi-fixed costs over a much larger
number of patients than that included in the study sample.
If, for example, improvements in patient management due to
the intervention could be maintained for several years into
the future (i.e. for the 14 intervention-group EDs), then many
more patients would receive the benefits of these improve-
ments without the need for any further investment. In this
scenario, cost per patient would fall but treatment effects per
patient would remain much the same, resulting in a better
balance between costs and effects.
Finally, interpretation of results is complicated by the lack
of widely accepted funding thresholds for the primary and
secondary outcomes. While patient-reported outcomes in
the NET-Plus sample included SF12-based SF6D index
scores, we were unable to identify secondary data mapping
the time path of HRQoL in mTBI patients and decided a
priori of commencement of the study not to calculate
QALYs by combining SF6D index scores with duration. For
clinical practice outcomes and clinical health outcomes, a
direct estimate of the funding threshold may have facilitated
the interpretation of cost-effectiveness results. We were not
able to identify direct estimates of the threshold in the litera-
ture, and it was not feasible to derive our own estimates as
part of the NET study. In recognition of such difficulties, we
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make significant efforts to quantify and illustrate decision
uncertainty and to couch results in terms of familiar funding
decisions (such as whether or not to fund an intervention at
a given cost per QALY). Such efforts allowed us to draw
clear policy recommendations from our findings despite the
lack of widely accepted funding or cost-effectiveness thresh-
olds for the primary and secondary outcomes.
Conclusion
The substantial upfront cost of the NET intervention
was not offset by savings in health service utilisation and
the NET intervention would therefore need to deliver
significant improvements in clinical practice and/or pa-
tient outcomes in order for it to be considered cost-ef-
fective. As delivered in the trial, the NET intervention
does appear to improve management of mTBI in the ED
but funding thresholds for these improvements would
need to be set implausibly high in order to justify the
additional cost of the intervention. This finding serves as
a timely reminder that initiatives to increase adherence
to guideline recommendations should themselves offer
good value for money.
The NET intervention was designed to maximise ef-
fectiveness subject to organisational constraints. Further
gains in effectiveness may therefore be difficult to
achieve without relaxing these organisational con-
straints. However, it may be possible to achieve a better
balance between costs and outcomes by scaling and
streamlining the NET intervention, potentially achieving
the same or smaller changes in clinical practice but at a
lower cost. This has broader implications for the design
of implementation interventions—perhaps suggesting
greater consideration should be given to smaller bang
for (smaller) buck strategies.
Endnotes
1Preference-based HRQoL weights from the SF12-based
SF6D must be combined with a period of time to permit
estimation of intervention effects in QALY terms (and in-
cremental cost-effectiveness in cost per QALY terms). For
the NET study, SF12 data was available for a single time
point, some 7 months post-discharge (on average). In the
absence of repeated observation on HRQoL, we will treat
measures of HRQoL as a summary measure of the effect
of the intervention with respect to anxiety, sleep, function-
ing, and adverse effects at a single point in time and we
make no attempt to combine SF6D index scores with time
for the purposes of calculating QALYs.
2The protocol specified a time horizon for the NET-Plus
sample to coincide with the final follow-up for the NET-Plus
sample, originally planned to take place at 3 months
post-injury. Due to delays in recruitment, follow-up for
NET-Plus patients occurred much later and over a much
longer period than planned (mean = 210 days post discharge;
SD 38.5 days; IQR 181–239; min = 130, max = 321). In such
circumstances, using patient self-report on a 4-week window
of health service utilisation to calculate per diems and then
multiplying out over the entire period from discharge to
follow-up would amplify any measurement errors due to re-
call bias or timing. We therefore treat patient self-report on
health service utilisation as representative of a 4-week period,
post-discharge from their initial mTBI presentation and take
this period as the time horizon for economic evaluations in
the NET-Plus sample.
3Recommendations to fund a new intervention or
change clinical practice are only consistent with maxi-
mising population health if they deliver a unit of the out-
come of interest at a better price than is on offer
elsewhere (i.e. better than interventions that are not or
will not be funded if the new intervention or policy
change is recommended). Decision-makers therefore
need to know the price at which they can buy a unit of
health outcome via the evaluated intervention or policy
change (captured by the incremental cost effectiveness
ratio) and the price at which alternative interventions
could deliver that same health outcome (captured by the
funding threshold, also known as the cost-effectiveness
threshold or reference ICER). As Edney et al. [34] put it,
“funding of a new technology with an ICER greater than
the reference ICER results in a net decrease in popula-
tion health, as represented by net QALY losses” (p248).
4Using a new approach, Edney et al. [34] estimated the
reference ICER for the Australian health care system at
AUD28033 (95%CI AUD20758–AUD37667). This is
broadly consistent with estimates for Australia (95%CI
AUD28904, AUD51470 at current exchange rates) reported
by Woods et al. [37] but much lower than the ballpark fig-
ure of AUD50000 per QALY that has been suggested as a
rule-of-thumb for decision-makers [38] and much lower
than previous estimates based on stated and revealed pref-
erence methods. For example, George et al. [39] estimated
the threshold or reference ICER at between AUD42000 and
AUD76000 using past funding decisions to intuit the re-
vealed preferences of decision-makers. Shiroiwa et al. [40]
estimated the funding threshold using a stated preference
approach (maximum social willingness to pay per QALY)
at between AUD64000 and AUD89000 (with higher/lower
estimates for different sub-populations).
5Calculated by dividing the funding threshold expressed
in cost per QALY terms by the upper confidence limit on
the cost-effectiveness ratio for the outcome of interest.
For cost per additional patient appropriately screened for
PTA, this calculation is $50,000/$2055 for the parametric
95%CI and $50,000/$2066 for the non-parametric 95%CI
(see Table 5 and accompanying discussion). This calcula-
tion gives us 24.33 additional patients appropriately
screened for PTA per QALY (or 0.04 QALYs per patient
appropriately screened for PTA).
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6NET is the most cost-effective alternative for over
80% of the distribution if the funding threshold exceeds
$34,000 per point improvement in SF6D index scores
(where a point improvement is a full 0 (death) to 1 (full
health) improvement at a single point in time). The ratio
of cost per point improvement in SF6D index scores and
cost per QALY ($34,000/$50,000) gives us the duration
(fraction of a year) over which the SF6D index scores
observed in the NET-Plus sample would have to persist
in order for $34,000 per point improvement in SF6D
index scores to be equivalent to a threshold of $50,000
per QALY. This calculation reflects the fact that QALYs
are the product of duration (in years) and SF6D index
scores, with one QALY being equivalent to 1 year with
an SF6D score equal to one.
7Only 60% of surveyed clinicians in intervention group
EDs claimed to have attended or watched a PTA session,
only 30% attended or watched CT session, and only 55%
attended or watched session on handing out patient
information.
8Doubling the cost of attendance time, travel time and
direct travel costs, and the cost of consumables for local
opinion leaders (to accommodate participation from 28
rather than 14 EDs) but leaving other costs associated
with delivery of the TTT workshops unchanged would see
the total cost of delivering the TTT workshops increase to
around $108,000 per 28 EDs, far less than double the cost
of delivery to 14 EDs. This would equate to a decrease in
the cost per ED from $5004 per ED (for 14 participating
EDs) to $3870 per ED (for 28 participating EDs).
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